Rupert Haynes is a healthcare executive with nearly three decades of experience in the pharmaceutical sector. Mr.Hayne’s most notable accomplishment as head of Global Marketing at GW Pharmaceuticals was leading the strategic development of the firm’s cannabinoid portfolio including the development of Epidiolex®, an FDA-approved cannabidiol for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Mr. Hayne’s led GW Pharmaceutical to be the first and only company in the world to develop an FDA approved cannabis-based drug. Before GW, Mr. Haynes held numerous commercial roles, including senior leadership positions, at both large pharma and bespoke biotech firms which include Sobi, UCB Pharma, Bristol-Myers Squibb Ltd, UK, and Pharmacia & Upjohn Ltd, UK. His field of expertise includes cannabinoid treatments for neurological, neurodegenerative and neuropsychological conditions.